Trial Profile
A Phase 2 Study of Imatinib Mesylate (Gleevec) as Maintenance Therapy After Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed C-kit Positive Acute Myeloid Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2022
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 20 Feb 2020 Status changed from active, no longer recruiting to completed.
- 14 Mar 2019 Planned End Date changed from 1 Apr 2013 to 9 Dec 2019.
- 08 Dec 2015 Primary endpoint (Progression-free survival for patients 60 years of age and older) has not been met as results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.